摘要
目的评估S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide(Sarm)对雄性骨质疏松大鼠的疗效。方法建立大鼠骨质疏松模型,皮下注射二氢睾酮(DHT)和Sarm治疗12周,测量骨密度(BMD)、骨生物力学、骨代谢相关血清生化指标和前列腺重量,综合评价Sarm对骨质疏松大鼠的疗效。结果与去势组相比,Sarm中、高剂量可以显著提高去势大鼠骨密度、生物力学参数,降低血清骨源性碱性磷酸酶(BALP)活性,未引起前列腺明显增生。结论Sarm能促进骨形成、防止骨量丢失,为骨质疏松的治疗提供了一种新方案。
Objective To evaluate the skeletal effects of s-3- （4-acetyla mino-phenoxy）-2-hydroxy-2-methyl-N-（4-nitro-3-trifluo- romethyl-phenyl）-propionamide in an osteopenic model. Methods Osteoporosis rats model was developed successfully by tcastrate, then treatment with subcutaneous injection of Dihydrotestosterone （DHT） and Sarm was applied in the next 12 weeks. Measurement of bone mineral density （BMD） and biomechanical properties of femur and lumbar vertebra, prostate weight and biochemical assays of serum were recorded after the termination of therapy. Results Compared with Ovx group,treatment using Sarm of middle and high doses markedly increased BMD and biomechanical properties,meanwhile,it decreased the levels of serum bone alkaline phosphatase （BALP）,but not to cause prostate significant hyperplasia. Conclusion The ability of Sarm to promote bone anabolism and prevent bone resorption. Position these drugs as promising new alternatives for the treatment of osteoporosis.
出处
《中国现代医生》
2011年第7期3-5,共3页
China Modern Doctor
